

EF-1 δ (3J6): sc-130371

BACKGROUND

EF-1 (elongation factor-1) is a multi-protein complex that is comprised of α , β , γ and δ subunits, all of which work together to ensure the delivery of amino-acyl-tRNAs to the ribosome, thereby elongating mRNA. EF-1 δ , also known as EEF1D, is a 281 amino acid subunit of the EF-1 complex. Functioning as a guanine nucleotide exchange factor, EF-1 δ stimulates the exchange of EF-1 α -bound GDP for GTP. Additionally, EF-1 δ is thought to interact with HIV-1 Tat and may repress host-cell mRNA transcription. Overexpression of EF-1 δ is associated with oesophageal carcinoma and may adversely affect the outcome of medulloblastomas, suggesting that the role that EF-1 δ plays in transcriptional elongation is important for the tight control and regulation of the cell cycle. Multiple isoforms of EF-1 δ exist due to alternative splicing events.

REFERENCES

1. Kawaguchi, Y., et al. 2003. Conserved protein kinases encoded by herpesviruses and cellular protein kinase Cdc2 target the same phosphorylation site in eukaryotic elongation factor-1 δ . *J. Virol.* 77: 2359-2368.
2. Cans, C., et al. 2003. Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. *Proc. Natl. Acad. Sci. USA* 100: 13892-13897.
3. Kapp, L.D., et al. 2004. The molecular mechanics of eukaryotic translation. *Annu. Rev. Biochem.* 73: 657-704.
4. Ogawa, K., et al. 2004. Clinical significance of elongation factor-1 δ mRNA expression in oesophageal carcinoma. *Br. J. Cancer* 91: 282-286.
5. Brandenberger, R., et al. 2004. Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation. *Nat. Biotechnol.* 22: 707-716.
6. De Bortoli, M., et al. 2006. Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. *BMC Cancer* 6: 223.
7. Beranova-Giorgianni, S., et al. 2006. Phosphoproteomic analysis of the human pituitary. *Pituitary* 9: 109-120.
8. Yang, S., et al. 2007. BMP-6 promotes E-cadherin expression through repressing EF-1 δ in breast cancer cells. *BMC Cancer* 7: 211.
9. Liao, J.Y., et al. 2008. A study on the fundamental factors determining the efficacy of siRNAs with high C/G contents. *Cell. Mol. Biol. Lett.* 13: 283-302.

CHROMOSOMAL LOCATION

Genetic locus: EEF1D (human) mapping to 8q24.3; Eef1d (mouse) mapping to 15 D3.

SOURCE

EF-1 δ (3J6) is a mouse monoclonal antibody raised against recombinant EF-1 δ of human origin.

PRODUCT

Each vial contains 100 μ g IgG_{2a} kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

EF-1 δ (3J6) is recommended for detection of EF-1 δ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)].

Suitable for use as control antibody for EF-1 δ siRNA (h): sc-77235, EF-1 δ siRNA (m): sc-77237, EF-1 δ shRNA Plasmid (h): sc-77235-SH, EF-1 δ shRNA Plasmid (m): sc-77237-SH, EF-1 δ shRNA (h) Lentiviral Particles: sc-77235-V and EF-1 δ shRNA (m) Lentiviral Particles: sc-77237-V.


Molecular Weight of EF-1 δ : 31 kDa.

Positive Controls: Hep G2 cell lysate: sc-2227, NTERA-2 cl.D1 whole cell lysate: sc-364181 or HeLa whole cell lysate: sc-2200.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml).

DATA



EF-1 δ (3J6): sc-130371. Western blot analysis of EF-1 δ expression in Hep G2 (A), NTERA-2 cl.D1 (B), HeLa (C) and HL-60 (D) whole cell lysates.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.